“A PK-PD/TD Model of Gemcitabine and Nab-Paclitaxel Chemotherapy in Pancreatic Cancer: Dose Schedule Adjustment May Minimize Severe Peripheral Neuropathy while Maintaining Antitumor Effects”

https://pubmed.ncbi.nlm.nih.gov/38117301

This study develops a PK-PD/TD model of gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer, finding that adjusting the dose schedule to every 2 weeks could be a more effective approach than dose reduction for minimizing severe peripheral neuropathy while maintaining antitumor effects.